Linden Thomas Advisory Services LLC Increases Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Linden Thomas Advisory Services LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 34,134 shares of the biopharmaceutical company’s stock after buying an additional 2,153 shares during the quarter. Gilead Sciences comprises 0.5% of Linden Thomas Advisory Services LLC’s portfolio, making the stock its 27th largest position. Linden Thomas Advisory Services LLC’s holdings in Gilead Sciences were worth $2,765,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. OFI Invest Asset Management purchased a new position in shares of Gilead Sciences during the third quarter valued at about $26,000. Tompkins Financial Corp boosted its stake in Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 241 shares in the last quarter. Fortitude Family Office LLC bought a new stake in Gilead Sciences during the fourth quarter worth about $29,000. Rakuten Securities Inc. bought a new stake in Gilead Sciences during the fourth quarter worth about $33,000. Finally, Financial Connections Group Inc. bought a new stake in Gilead Sciences during the fourth quarter worth about $40,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.29% of the stock is owned by company insiders.

Gilead Sciences Stock Performance

GILD stock traded up $0.38 during midday trading on Tuesday, reaching $67.33. 2,815,205 shares of the company’s stock traded hands, compared to its average volume of 7,270,208. The stock’s 50-day moving average is $71.81 and its 200 day moving average is $76.51. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The stock has a market cap of $83.83 billion, a P/E ratio of 14.88, a PEG ratio of 0.92 and a beta of 0.19. Gilead Sciences, Inc. has a 52-week low of $65.90 and a 52-week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The firm had revenue of $7.12 billion during the quarter, compared to analysts’ expectations of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same period last year, the company earned $1.67 earnings per share. As a group, analysts anticipate that Gilead Sciences, Inc. will post 6.55 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were given a dividend of $0.77 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.57%. Gilead Sciences’s dividend payout ratio is currently 68.44%.

Wall Street Analyst Weigh In

GILD has been the topic of several research reports. StockNews.com lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday. Royal Bank of Canada dropped their target price on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 14th. Mizuho dropped their target price on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. Barclays dropped their target price on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research note on Monday, February 12th. Finally, Wells Fargo & Company dropped their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research note on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $84.71.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.